User profiles for A. Seferian

Andrei Seferian

Université Paris-Sud, Hôpital Bicêtre, AP-HP, Inserm UMR-S999, 78 Rue du Général …
Verified email at bct.aphp.fr
Cited by 2934

Pathogenesis of pulmonary arterial hypertension: lessons from cancer

…, N Ricard, C Sattler, A Seferian… - European …, 2013 - Eur Respiratory Soc
Although the causal pathomechanisms contributing to remodelling of the pulmonary vascular
bed in pulmonary arterial hypertension (PAH) are still unclear, several analogous features …

Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?

A Seferian, G Simonneau - European Respiratory Review, 2013 - Eur Respiratory Soc
Pulmonary arterial hypertension (PAH) is a progressive disease characterised by remodelling
of small pulmonary arteries leading to an increased pulmonary vascular resistance, right …

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre …

…, N Mendonca, A Lavrov, A Seferian… - The Lancet …, 2021 - thelancet.com
Background Spinal muscular atrophy is a rare, autosomal recessive, neuromuscular disease
caused by biallelic loss of the survival motor neuron 1 (SMN1) gene, resulting in motor …

The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements

…, C Rotondo, M Rubio-Rivas, A Seferian… - The Lancet …, 2020 - thelancet.com
Background Systemic sclerosis-associated interstitial lung disease (ILD) carries a high
mortality risk; expert guidance is required to aid early recognition and treatment. We aimed to …

Drug-induced pulmonary arterial hypertension: a recent outbreak

D Montani, A Seferian, L Savale… - European …, 2013 - Eur Respiratory Soc
Pulmonary arterial hypertension (PAH) is a rare disorder characterised by progressive
obliteration of the pulmonary microvasculature resulting in elevated pulmonary vascular …

Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension

…, M Riou, P Roblot, O Sanchez, A Seferian… - American journal of …, 2021 - atsjournals.org
Rationale: The relationship between the initial treatment strategy and survival in pulmonary
arterial hypertension (PAH) remains uncertain. Objectives: To evaluate the long-term survival …

Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial

…, O Boespflug-Tanguy, S De Lucia, A Seferian… - The Lancet …, 2022 - thelancet.com
Background Risdiplam is an orally administered therapy that modifies pre-mRNA splicing of
the survival of motor neuron 2 (SMN2) gene and is approved for the treatment of spinal …

Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation

…, S Bulifon, X Jaïs, F Parent, A Seferian… - European …, 2020 - Eur Respiratory Soc
Background Viral respiratory infections are the main causes of asthma exacerbation. The
susceptibility of patients with asthma to develop an exacerbation when they present with …

Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension

…, A Berezne, P Dorfmüller, A Seferian… - Arthritis & …, 2012 - Wiley Online Library
Objective Pulmonary venoocclusive disease (PVOD) is an uncommon form of pulmonary
hypertension (PH) characterized by obstruction of small pulmonary veins. Pulmonary venous …

[HTML][HTML] Prospective and longitudinal natural history study of patients with type 2 and 3 spinal muscular atrophy: baseline data NatHis-SMA study

A Chabanon, AM Seferian, A Daron, Y Péréon… - PLoS …, 2018 - journals.plos.org
Spinal muscular atrophy (SMA) is a monogenic disorder caused by loss of function mutations
in the survival motor neuron 1 gene, which results in a broad range of disease severity, …